PROBASE试验:年轻男性前列腺癌筛查中MRI靶向活检加做系统穿刺的价值
该多中心前瞻性筛查 trial 纳入525例45-54岁、PSA≥3.0 ng/ml的男性,行多参数MRI后联合靶向穿刺(TBx,每病灶2针)与系统穿刺(SBx)。209例检出前列腺癌,其中148例为临床显著癌(csPC,GG≥2)。SBx漏诊24/148例csPC(16%),TBx漏诊49/148例(33%);TBx对MRI可见病灶的靶向准确性有限,年轻男性可能需加做SBx或病灶周围取样。
要点
- 每病灶仅2针的TBx漏诊33%的csPC,SBx漏诊16%,TBx靶向准确性不足。
- SBx较TBx多检出25例低危前列腺癌(51 vs 26)。
- 64%的SBx分级高于TBx的病例,其阳性针位于MRI病灶内。
核心结论
- 每病灶2针的TBx漏诊了相当比例的csPC,尽管这些病例在MRI上被正确识别,提示靶向准确性或融合技术存在局限。
- 对年轻男性,尤其前列腺体积较小者,加做SBx或病灶周围靶向取样可能是确保可靠早期检出(cs)PC的有价值补充。
研究设计与样本
- 多中心前瞻性筛查试验(PROBASE,ISRCTN37591328)的回顾性亚组分析。
- 2014年2月至2023年8月纳入525例45-54岁、确认PSA≥3.0 ng/ml的男性,行多参数MRI后联合TBx(每病灶2针,软件融合)与SBx(经直肠或经会阴)。
主要发现
- 209例(39%)检出前列腺癌,其中148/209例(71%)为csPC(GG≥2)。
- SBx漏诊24/148例csPC(16%),TBx漏诊49/148例(33%)。
- SBx较TBx多检出25例低危前列腺癌(51 vs 26)。
- SBx分级高于TBx的病例共89例(含GG1),其中64%的阳性针位于MRI检出病灶内。
- 5例GG≥3的前列腺癌在MRI上未显示。
临床怎么用
- 对45-54岁PSA≥3.0 ng/ml的筛查男性,不应仅依赖每病灶2针的TBx,应考虑加做SBx或病灶周围取样以减少csPC漏诊。
- 前列腺体积较小的年轻男性可能尤其需要补充系统取样。
局限性
- 活检前缺乏中心化MRI复核。
- 活检技术存在变异。
- 为回顾性亚组分析。
- 随访时间短。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: While magnetic resonance imaging (MRI)-guided targeted biopsy (TBx) is becoming an integral part of early detection of prostate cancer (PC), its role in screening of younger men remains unclear. We analyzed the additional value of systematic biopsy (SBx) in improving detection of clinically significant PC (csPC). METHODS: A total of 525 men aged 45-54 yr with confirmed prostate-specific antigen ≥3.0 ng/ml underwent multiparametric MRI followed by combined TBx and SBx between February 2014 and August 2023 within a multicenter prospective screening trial in Germany. Software-based MRI/ultrasound fusion TBx (2 cores per lesion) combined with SBx was performed via a transrectal or transperineal approach. The primary objective was to analyze differences in csPC detection rates between SBx and TBx in relation to MRI. Secondary objectives were detection rates by International Society of Urological Pathology grade group (GG) and the distribution of SBx and/or TBx findings. KEY FINDINGS AND LIMITATIONS: PC was detected in 209 men (39%), of which 148/209 cases were csPC (71%; GG ≥2). SBx missed 24/148 csPC cases (16%) and TBx missed 49/148 (33%). SBx detected 25 more low-risk PC cases than TBx (51 vs 26). For 64% of the cases in which SBx detected higher GG than TBx (n = 89, including GG 1), the positive cores were located within MRI-detected lesions. Five GG ≥3 PC cases were not identified on MRI. Limitations include the lack of centralized MRI review before biopsy, variability in biopsy technique, retrospective subgroup analysis, and short follow-up. CONCLUSIONS AND CLINICAL IMPLICATIONS: A relevant proportion of csPC cases were missed by two-core TBx, although they were correctly identified on MRI, suggesting limitations in targeting accuracy and/or the fusion technique. SBx cores or targeted perilesional sampling, particularly in young men with smaller prostate volume, might be a valuable complement to TBx to ensure reliable and early detection of (cs)PC in this age group. PATIENT SUMMARY: We looked at the effectiveness of systematic biopsy (usually 12 cores taken from the prostate gland) and targeted biopsy (cores from a suspicious area seen on a scan) of the prostate among men aged 45-54 years as part of a prostate cancer screening trial. The results show that using only two targeted cores per lesion seen on an MRI (magnetic resonance imaging) scan may miss a significant number of clinically relevant prostate cancers. One reason could be that MRI-targeted biopsies are not always perfectly accurate. To improve diagnostic accuracy in younger men, it may be necessary to take additional systematic tissue samples, or at least more samples from around any suspicious area. This trial is registered on ISRCTN as ISRCTN37591328.
引用
- Al-Monajjed R, Boschheidgen M, Lakes J, et al. Value of Additional Systematic Cores During Magnetic Resonance Imaging-guided Targeted Biopsy in Prostate Cancer Screening for Young Men: Results from the PROBASE Trial. Eur Urol Oncol. 2025. PMID: 41219113. doi:10.1016/j.euo.2025.10.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。